Drug intelligence / Profile preview

SPARC1316

Development stage: Phase 2
Lead developer: SPARC
Modality: Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

SPARC1316 (also known as SUN 0597 or S0597) is a dry powder inhaler formulation developed by Sun Pharma Advanced Research Company Limited for oral inhalation. It has been investigated in Phase 1/2a clinical trials for the treatment of asthma. The drug was evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and asthma patients. The precise mechanism of action has not been disclosed in public sources[1][2][3].

Other names: SPARC1316SPARC-1316SPARC 1316SUN 0597SUN0597SUN-0597S0597S-0597S 0597

Beyond the preview

Go deeper on SPARC1316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1316.

Explore the full profile